HOSA-Future Health Professionals’ Post

Very informative session ahead! 💯 Do join!

Missed Dr. Ghulam Abbas on WDTV First at 4? Catch up now & hear about the latest in Thoracic Oncology with insights on his specialized services at Mon Health. Click below to watch the recap. #MonHealth #ThoracicOncology #ThoracicSurgery

How Often did You Use Abemaciclib in EBC(Monarche)? #one_on_one with #barsoum with Dr. Fabrice Andre, President of the European Society for Medical Oncology #esmo Powered by #boc_onco_science_school #B_O_S_S Knows How to Make Medical Learning and Education Interesting and Exciting 😉 https://lnkd.in/dj6sTdR4

In this episode, host Dr. Bryan Hartley takes us on a deep dive into the origin story and mission of Pulmera, a medtech company dedicated to transforming the field of bronchoscopic lung cancer diagnosis by retrofitting existing fluoroscopy machines into cone beam CT-like scanners. Dr. Hartley is an interventional radiologist and co-founder Pulmera. Pulmera is developing a novel approach to enhance physicians’ ability to diagnose lung nodules accurately through innovative technology. Dr. Hartley shares insights into the challenges of existing diagnostic methods, the inspiration behind Pulmera, and the technology’s potential to combine the best of 3D imaging and endoscopy techniques. Dr. Hartley discusses the benefits for both patients and physicians, such as improved diagnostic yields and patient outcomes, and introduces an investment opportunity for the BackTable community to be part of this revolutionary project. The episode also explores the broader implications of this technology across various medical specialties beyond pulmonology. Stream here: https://lnkd.in/e7bMQteX #InterventionalRadiology #InterventionalPulmonology #Pulmonology #PhysicianEntrepreneur #StartUp #LungNodule #MedicalImaging #INN74

The landscape of personalized cancer therapies is constantly evolving. TIL therapies have garnered recent attention following the first #FDA approval in the class in March of this year. How might TIL therapies impact the landscape of #cancer treatment moving forward? In our latest blog, we explore the opportunities and challenges in leveraging TIL therapies. Learn more about commercial implications and strategies for advancing TIL therapies here: https://bit.ly/3Wx90QY Vivek Mittal, Ned Wydysh, Earl Gillespie, Matthew Chin, Meghan Lu

It is exciting to see the recent publication of the first performance recommendations for blood-based biomarker (BBM) tests by CEOi - Global CEO Initiative on Alzheimer's Disease. This manuscript, “The Global CEO Initiative on Alzheimer’s Disease performance recommendations for blood-based biomarker tests,” was created by leading experts in the field and is now available in Nature Reviews Neurology.  Given their accessibility and affordability compared to other tools, BBMs offer the potential to improve equity in Alzheimer’s care. Progress! https://lnkd.in/eaYy5M6e

YOUR health is always a priority us. Dr. Ryan Walker shared important insights on First at 4 about the significance of regular screenings. If you are 45 or older, now is the time to schedule your colon cancer screening. Early detection saves lives! Talk to a primary care provider today & ensure you have a dedicated partner in your health journey. Visit https://lnkd.in/egAajy7q to request an appointment if you do not have a Primary Care provider & watch Dr. Walker’s segment below. #MonHealth #ColonCancerAwareness #PrimaryCare #ColonCancerScreening

Check out the first episode of our new series #TulaneMedInsider! I'm excited to start putting these videos out regularly on the first Monday of each month. Tulane University School of Medicine

#ProjectOptimus represents a major update to clinical trial design. How should developers adapt and what does it mean for commercial success? Find out more in our latest blog! #oncology #clinicaltrials #HealthAdvances

The announcement of FDA’s #oncology dose optimization initiative, #ProjectOptimus, is a long-coming step towards improving dosing of targeted oncology therapies. With this initiative, the #FDA extends guidance on clinical trial design for targeted therapies. While these guidelines should improve patient safety and QOL, the long-term implications for the commercialization of anticancer drugs are still unfolding. In our most recent blog, we discuss the potential commercial ramifications of Project Optimus, drawing on recent analogs including #lumakras, and highlight the possible impacts on the targeted therapy pipeline. Read here: https://bit.ly/3K752r9 Vivek Mittal, Gary Gustavsen, Ned Wydysh, Earl Gillespie, Arpit Dave, Ph.D., Ashley Peake